← Back to all trials
Recruiting
NCT05655351
Effect of a Vaccination Against COVID-19 on Monocyte Production of Oxygenated Derivatives.
Conditions: CORONAVIRUS INFECTIONS
Sex: All
Ages: 18 Years – N/A
Phase: EARLY_PHASE1
Enrollment: 30
Sponsor: Centre Hospitalier Universitaire de Nīmes
Location: France
Summary
Knowing that the vaccine antigen includes the ACE2 binding moiety (RBD), the hypothesis is that circulating vaccine antigen could reduce the enzymatic activity of ACE2, and thus increase circulating AngII concentration, monocyte ROS production and lymphocyte apoptosis.
This hypothesis is supported by the fact that the Spike protein of SARSCoV-1, which uses the same receptor as SARS-CoV-2, induces a decrease in expression and activation of the Angiotensin II pathway in mice (Kuba et al. 2005).
Eligibility Criteria
Inclusion Criteria:Candidate for SARS-CoV-2 vaccination with an mRNA vaccine (Pfizer, Moderna).Subject has given free and informed consent.Subject who has signed the consent form.Person affiliated to or beneficiary of a health insurance plan.Exclusion Criteria:Patients under treatment with N-acetylcysteine or sartan.Patients with a dysimmune pathology or immunosuppressive treatment.Person infected with SARS-CoV-2 within 3 months prior to inclusion.Person participating in a category 1 defined RIPH.Subject in an exclusion period as determined by another study.Person under court protection, guardianship or trusteeship.Subject who is unable to give consent.Subject for whom it is impossible to give clear information.Pregnant or breastfeeding woman.
Source: ClinicalTrials.gov (NCT05655351). StuddyBuddy aggregates publicly available trial information.